Status: Recruiting
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
This will be a single center, prospective, open-label, randomized, controlled trial comparing Envarsus XR® to twice-daily tacrolimus. The targeted population will be patients with end stage renal disease listed for primary solitary kidney transplant. Transplant Surgery is not part of the study.
Participants needed: 78
Trial details
Phase: Phase 2, Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Roberto GedalyUpdated: Mar 24, 2026Locations: 1
Eligibility criteria
Fluent in English able to understand and provide informed consent. [+3]
Previously undergone organ, tissue or cell transplant [+13]